We don't anticipate the impact will be that significant, because we didn't go nearly as far as the EU wanted us to go. They have additional patent term protection of about five years, whereas we have agreed to an additional two years under very specific circumstances, with a number of exemptions to that as well.
During the negotiations, we consulted closely with the brand-name companies and very closely with the generic companies. They have largely supported the outcome on CETA, because we were able to attain many of the objectives that they had in the negotiations. They wanted an exemption for exports, and we got that. They wanted no retroactivity, and we got that. They wanted it to apply to a single patent, not multiple patents, and we got that. We have exclusions for pediatric extensions; we got that. As a result, I think we've tailored it in a way that we don't anticipate huge impacts.